´╗┐MIME-Version: 1.0 X-Document-Type: Workbook Content-Type: multipart/related; boundary="----=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477" This document is a Single File Web Page, also known as a Web Archive file. If you are seeing this message, your browser or editor doesn't support Web Archive files. Please download a browser that supports Web Archive, such as Microsoft Internet Explorer. ------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Workbook.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"

This page should be opened with Microsoft Excel XP or newer.

------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet01.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Document and Entity Information
12 Months Ended
Dec. 31, 2013
Mar. 31, 2014
Document and Entity Information [Abstract] ' '
Entity Registrant Name 'DelMar Pharmaceuticals, Inc. '
Entity Central Index Key '0001498382 '
Trading Symbol 'dmpi '
Entity Current Reporting Status 'Yes '
Entity Voluntary Filers 'No '
Current Fiscal Year End Date '--12-31 '
Entity Filer Category 'Smaller Reporting Company '
Entity Common Stock, Shares Outstanding ' 0
Document Type '10-Q '
Document Period End Date Mar 31, 2014 '
Amendment Flag 'false '
Document Fiscal Year Focus '2014 '
Document Fiscal Period Focus 'Q1 '
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet02.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Consolidated Balance Sheets (USD $)
Mar. 31, 2014
Dec. 31, 2013
Current assets ' '
Cash and cash equivalents $ 3,474,150 $ 4,136,803
Taxes and other receivables 10,419 11,062
Prepaid expenses 269,584 170,883
Assets, total 3,754,153 4,318,748
Current liabilities ' '
Accounts payable and accrued liabilities 404,413 140,457
Related party payables 35,798 109,030
Current liabilities, total 440,211 249,487
Loan payable to Valent 274,387 272,372
Stock option liability 241,863 212,561
Derivative liability 5,857,991 4,402,306
Liabilities, total 6,814,452 5,136,726
Stockholders' Deficiency ' '
Preferred stock Authorized 5,000,000 shares, $0.001 par value 1 share outstanding at March 31, 2014 (December 31, 2013 - 1) '   '  
Common stock Authorized 200,000,000 shares, $0.001 par value Issued 32,082,132 at March 31 2014 (December 31, 2013 - 31,534,819) 32,082 31,535
Additional paid-in capital 9,748,010 8,791,715
Warrants 6,201,544 6,202,100
Deficit accumulated during the development stage (19,063,113) (15,864,506)
Accumulated other comprehensive income 21,178 21,178
Stockholders' equity, total (3,060,299) (817,978)
Liabilities and equity, total $ 3,754,153 $ 4,318,748
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet03.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Consolidated Balance Sheets (Parenthetical) (USD $)
Mar. 31, 2014
Dec. 31, 2013
Statement of Financial Position [Abstract] ' '
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares outstanding 1 1
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 200,000,000 200,000,000
Common stock, shares issued (in shares) 32,082,132 31,534,819
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet04.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Consolidated Statements of Operations and Comprehensive Loss (USD $)
3 Months Ended 48 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Mar. 31, 2014
Expenses ' ' '
Research and development expense $ 618,869 $ 631,947 $ 5,604,809
General and administrative expense 966,923 920,377 6,383,235
Operating expenses, total 1,585,792 1,552,324 11,988,044
Other loss (income) ' ' '
Change in fair value of derivative liability 1,599,349 2,543,574 (43,204)
Issuance of shares to Valent for future royalty reduction '   598,000 598,000
Derivative issue costs '   2,713,220 2,737,962
Foreign exchange loss (gain) 11,947 (3,754) 14,125
Interest expense 2,015 1,955 39,489
Interest income (496) 0 (2,987)
Nonoperating Income (Expense) 1,612,815 5,852,995 3,343,385
Net loss for the period 3,198,607 7,405,319 15,331,429
Basic and diluted loss per share $ (0.1) $ (0.3) '  
Weighted average number of shares 31,659,791 24,316,325 '  
Comprehensive loss ' ' '
Net loss 3,198,607 7,405,319 15,331,429
Other comprehensive income ' ' '
Translation to US dollar presentation currency '   '   (21,178)
Comprehensive loss $ 3,198,607 $ 7,405,319 $ 15,310,251
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet05.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Consolidated Statements of Cash Flows
3 Months Ended 48 Months Ended
Mar. 31, 2014
USD ($)
Mar. 31, 2013
USD ($)
Mar. 31, 2014
USD ($)
Cash flows from operating activities ' ' '
Loss for the period $ (3,198,607) $ (7,405,319) $ (15,331,429)
Items not affecting cash ' ' '
Accrued interest 2,015 1,955 24,387
Change in fair value of derivative liability 1,599,349 2,543,574 (43,204)
Shares issued to Valent for future royalty reduction '   598,000 598,000
Non-cash derivative issue costs '   2,201,008 2,201,008
Units issued for services '   '   275,284
Warrants issued for patents '   '   89,432
Warrants issued for services '   '   173,399
Stock-based compensation 620,074 272,902 4,024,311
Prototype drug product '   '   250,000
Net income (loss) after adjustments of non-cash items (977,169) (1,787,880) (7,738,812)
Changes in non-cash working capital ' ' '
Taxes and other receivables 643 (31,395) (10,419)
Prepaid expenses (98,701) (54,752) (269,584)
Accounts payable and accrued liabilities 263,956 (98,722) 631,331
Related party payables (73,232) (151,718) 35,798
Changes in non-cash working capital 92,666 (336,587) 387,126
Net cash flows from operating activities (884,503) (2,124,467) (7,351,686)
Cash flows from financing activities ' ' '
Net proceeds from the exercise of warrants 221,850 '   221,850
Net proceeds from the issuance of units '   9,639,520 10,501,916
Net proceeds from the issuance of common shares '   '   102,070
Net cash flows from financing activities 221,850 9,639,520 10,825,836
Increase in cash and cash equivalents (662,653) 7,515,053 3,474,150
Cash and cash equivalents - beginning of period 4,136,803 17,782 '  
Cash and cash equivalents - end of period 3,474,150 7,532,835 3,474,150
Supplementary information ' ' '
Issuance of shares for the settlement of accounts payable '   '   253,050
Issuance of units for the settlement of accounts payable '   '   23,785
Non-cash share issuance costs '   6,288,594 6,302,889
Settlement of accounts payable with a loan payable '   '   250,000
Cashless exercise of Placement Agent Warrants '   '   239,600
Exercise of CDN $0.50 Warrants for no additional consideration (note 4) 17,600 '   259,315
Deferred costs '   $ 90,771 '  
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet06.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Consolidated Statements of Cash Flows (Parenthetical)
3 Months Ended
Mar. 31, 2014
CDN
Issuance of units/warrants at net of cash issue costs 0.5
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet07.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Going concern and nature of operations
3 Months Ended
Mar. 31, 2014
Nature of Operations and Going Concern [Abstract] '
Nature of operations and going concern '
1  
Going concern and nature of operations
 
Going concern
 
For the three months ended March 31, 2014, the Company reported a loss of $3,198,607 and an accumulated deficit of $19,063,113 at that date. As at March 31, 2014 the Company had cash and cash equivalents on hand of $3,474,150. The Company does not have the prospect of achieving revenues in the near future and the Company will require additional funding to maintain its research and development projects and for general operations. These circumstances lend substantial doubt as to the ability of the Company to meet its obligations as they come due. The expenses to be incurred in developing and pursuing our Company’s business plan have a large degree of uncertainty.  In addition, the Company has not begun to commercialize or generate revenues from any product candidate.
 
Consequently, management is pursuing various financing alternatives to fund the Company’s operations so it can continue as a going concern in the medium to longer term. Accordingly, the Company is considered to be in the development stage as defined in Accounting Standards Codification (ASC) 915-10. We believe, based on our current estimates and plans that we have enough cash to fund our operations for the next 9 to 12 months. Management plans to secure the necessary financing through the issue of new equity and/or the entering into of strategic partnership arrangements. Nevertheless, there is no assurance that these initiatives will be successful.
 
These financial statements have been prepared on a going concern basis which assumes that the Company will continue its operations for the foreseeable future and contemplates the realization of assets and the settlement of liabilities in the normal course of business.
 
The conditions and risks noted above cast substantial doubt on the validity of that assumption. These financial statements do not give effect to any adjustments to the amounts and classification of assets and liabilities that may be necessary and could potentially be material, should the Company be unable to continue as a going concern.
 
Nature of operations
 
DelMar Pharmaceuticals, Inc. (the “Company”) is a Nevada corporation formed on June 24, 2009 under the name Berry Only Inc.  On January 25, 2013 the Company acquired (either directly or indirectly) (the “Reverse Acquisition”) all of the issued and outstanding shares of DelMar Pharmaceuticals (BC) Ltd. (“DelMar BC”). Prior to the Reverse Acquisition, Berry did not have any significant assets or operations.  DelMar Pharmaceuticals, Inc. is the parent company of DelMar (BC), a British Columbia, Canada corporation incorporated on April 6, 2010, which is a development stage company with a focus on the development of drugs for the treatment of cancer.  It is also the parent company to 0959454 B.C. Ltd., a British Columbia corporation (“Callco”), and 0959456 B.C. Ltd., a British Columbia corporation (“Exchangeco”). Callco and Exchangeco were formed to facilitate the Reverse Acquisition.
  
As a result of the shareholders of DelMar (BC) having a controlling interest in the Company subsequent to the Reverse Acquisition, for accounting purposes the transaction is a capital transaction with DelMar (BC) being the accounting acquirer even though the legal acquirer is Berry. Therefore, the historic financial statements of DelMar (BC) are presented as the comparative balances for the periods prior to the Reverse Acquisition.
 
References to the Company refer to the Company and its wholly-owned subsidiaries, DelMar (BC), Callco and Exchangeco. References to Berry relate to the Company prior to the Reverse Acquisition.
 
The Company is a development stage company focused on the discovery and development of new medicines with the potential to treat cancer patients who have failed modern targeted or biologic therapy. The Company has initiated a clinical trial with its lead drug candidate VAL-083 for the treatment of refractory glioblastoma multiforme (“GBM”). The Phase I/II study is an open-label, single arm dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of VAL-083 in patients with histologically confirmed initial diagnosis of primary WHO Grade IV malignant glioma, now recurrent. Patients with prior low-grade glioma or anaplastic glioma are eligible if histologic assessment demonstrates transformation to GBM.
 
The address of the Company’s administrative offices is Suite 720 - 999 West Broadway, Vancouver, British Columbia, V5Z 1K5 with clinical operations located at 3485 Edison Way, Suite R, Menlo Park, California, 94025.
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet08.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Significant accounting policies
3 Months Ended
Mar. 31, 2014
Accounting Policies [Abstract] '
Significant accounting policies '
2  
Significant accounting policies
 
Basis of presentation
 
The consolidated condensed interim financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles (“US GAAP”) and are presented in United States dollars. The Company’s functional currency is the United States dollar.
 
In the quarter ended March 31, 2013, the Company’s functional currency changed from Canadian dollars to United States dollars as a result of various objective factors. Therefore translation of goods and services in a foreign currency are re-measured to the functional currency of the Company with gains and losses on re-measurement recorded in the consolidated condensed interim statement of loss. Any gains and losses that were previously recorded in accumulated other comprehensive income are unchanged from the date of the change of functional currency which was January 1, 2013.
 
The accompanying consolidated condensed interim financial statements include the accounts of the Company and its wholly-owned subsidiaries, DelMar BC, Callco, and Exchangeco. All intercompany balances and transactions have been eliminated.
 
The principal accounting policies applied in the preparation of these financial statements are set out below and have been consistently applied to all periods presented.
  
Unaudited interim financial data
 
The accompanying unaudited March 31, 2014 consolidated condensed interim balance sheets, the consolidated condensed interim statements of loss and comprehensive loss for the three months ended March 31, 2014 and 2013, and consolidated condensed cash flows for the three months ended March 31, 2014 and 2013, and the related interim information contained within the notes to the consolidated condensed interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and the notes required by accounting principles generally accepted in the United States for complete financial statements. These consolidated condensed interim financial statements should read in conjunction with the annual financial statements of the Company as at December 31, 2013 filed in our Form 10-K filed with the Securities and Exchange Commission on March 10, 2014. In the opinion of management, the unaudited consolidated condensed interim financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair statement of the Company’s financial position at March 31, 2014 and results of its operations for the three months ended March 31, 2014 and 2013, and its cash flows for the three months ended March 31, 2014 and 2013. The results for three months ended March 31, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014 or for any other future annual or interim period.
 
Use of estimates
 
The preparation of consolidated condensed interim financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end or during the reporting period.  Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liability and the valuation of equity instruments issued for services.  There have been no changes to the methodology used in determining these estimates from the year ended December 31, 2013.
 
Loss per share
 
Loss per share is calculated based on the weighted average number of common shares outstanding.  For the three month periods ended March 31, 2014 and March 31, 2013 respectively, diluted loss per share does not differ from basic loss per share since the effect of the Company’s warrants and stock options are anti-dilutive.  At March 31, 2014, potential common shares of 22,392,696 (March 31, 2013 – 24,985,009) relating to warrants and 3,240,000 (March 31, 2013 - 1,020,000) relating to stock options were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive.
  
Recent accounting pronouncements
 
The Company reviews new accounting standards as issued.  
 
The accounting pronouncements issued subsequent to the date of these financial statements that were considered significant by management were evaluated for the potential effect on these financial statements. Management does not believe any of the subsequent pronouncements will have a material effect on these financial statements as presented and does not anticipate the need for any future restatement of these financial statements because of the retro-active application of any accounting pronouncements issued subsequent to March 31, 2014 through the date these financial statements were issued.
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet09.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Related party transactions
3 Months Ended
Mar. 31, 2014
Related Party Transactions [Abstract] '
Related party transactions '
3  
Related party transactions
 
During the three months ended March 31, 2014
 
Pursuant to consulting agreements with the Company’s officers the Company pays a total of $32,000 per month in cash compensation to its officers. Pursuant to these agreements the Company recognized a total of $96,000 in compensation expense for the three months ended March 31, 2014.
 
Included in accounts payable at March 31, 2014 is an aggregate amount owing of $35,798 (December 31, 2013 - $74,754) to the Company’s officers and directors for fees and expenses. The Company pays related party payables incurred for fees and expenses under normal commercial terms.
 
The Company paid $24,000 in directors’ fees during the three months ended March 31, 2014.
 
During the three months ended March 31, 2013
 
Pursuant to consulting agreements with the Company’s officers and directors the Company pays a total of $36,784 per month to its officers and directors. Pursuant to these agreements the Company recognized a total of $110,352 in compensation expense for the three months ended March 31, 2013.
 
On January 25, 2013, in connection with the Reverse Acquisition (note 1), Valent was issued 1,150,000 shares of common stock of the Company in exchange for Valent agreeing to the reduction of certain future royalties payable to Valent under its Assignment Agreement with the Company. As a result of the share issuance the Company has recognized an expense of $598,000 for the three months ended March 31, 2013.
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet10.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Derivative liability
3 Months Ended
Mar. 31, 2014
Derivative liability [Abstract] '
Derivative liability '
4  
Derivative liability
 
The Company has issued stock purchase warrants. Based on the terms of certain of these warrants the Company determined that the warrants were a derivative liability which is recognized at fair value at the date of the transaction and re-measured at fair value each reporting period with the changes in fair value recorded in the consolidated condensed statement of loss and comprehensive loss.
 
CDN $0.50 Unit Warrants
 
During the three months ended March 31, 2014, 20,000 warrants were exercised for no additional consideration for 20,000 shares of common stock.  As a result, $17,600 of the derivative liability has been reclassified to equity.  The warrants that have been exercised were revalued at their exercise date and then the reclassification to equity was recorded.
 
The remaining 2,169,000 warrants expired on January 25, 2014.  As of March 31, 2014 there are no CDN $0.50 unit warrants outstanding.
 
Investor Warrants
 
During the three months ended March 31, 2014, 277,313 warrants were exercised for 277,313 shares of common stock.  The Company received proceeds of $221,850 from the exercise.  As a result, $126,064 of the derivative liability has been reclassified to equity.  The warrants that have been exercised were revalued at their exercise date and then the reclassification to equity was recorded.
 
The remaining 12,847,689 Investor Warrants issued with the units have been re-valued at March 31, 2014 using a simulated probability valuation model using the following assumptions:  dividend rate - 0%, volatility - 78%, risk free rate - 1.44% and a term of approximately four years.
 
Dividend Warrants
 
The Dividend Warrants have been measured at fair value at March 31, 2014 using a simulated probability valuation model using the following assumptions:  dividend rate - 0%, volatility - 78%, risk free rate - 1.44% and a term of approximately four years.
 
Warrants issued for services
 
The Company has issued 300,000 warrants for services.  The warrants were issued on September 12, 2013 and are exercisable on a cashless basis at an exercise price of $1.76 for five years.  The warrants have been measured at March 31, 2014 using a simulated probability valuation model using the following assumptions:  dividend rate - 0%, volatility -81%, risk free rate - 1.62% and a term of approximately 4.5 years.
  
The Company’s derivative liability is summarized as follows:
 
  
March 31,
2014
$
  
December 31,
2013
$
 
       
Opening balance
  4,402,306   121,000 
         
Issuance of units
  -   3,681,372 
Dividend Warrant liability acquired on reverse acquisition
  -   2,041,680 
Warrants issued for services
  -   124,020 
Change in fair value of unexercised warrants
  1,599,349   (1,324,051)
Reclassification to equity upon exercise of warrants
  (143,664)  (241,715)
         
Closing balance
  5,857,991   4,402,306 
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet11.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Stockholders' deficiency
3 Months Ended
Mar. 31, 2014
Stockholders' deficiency [Abstract] '
Stockholders' deficiency '
5  
Stockholders’ deficiency
 
Preferred stock
 
Authorized
5,000,000 preferred shares, $0.001 par value
 
Issued and outstanding at March 31, 2014 - 1 (December 31, 2013 - 1)
 
Common stock
 
Authorized
200,000,000 common shares, $0.001 par value
 
Issued and outstanding at March 31, 2014 – 32,082,132 (December 31, 2013 – 31,534,819).
 
The issued and outstanding common shares at March 31, 2014 include 7,169,583 shares of common stock on an as-exchanged basis with respect to the shares of Exchangeco that can be exchanged for shares of common stock of the Company.
 
   
Shares of common stock
outstanding
   
Common stock
   
Additional paid-in capital
   
Warrants
 
                         
Balance – December 31, 2013
    31,534,819       31,535       8,791,715       6,202,100  
                                 
Exercise of Investor Warrants
    277,313       277       221,573       -  
Exercise of CDN $0.50 unit warrants
    20,000       20       17,580       -  
Shares issued for services (a)
    250,000       250       314,750       -  
Reclassification of derivative liability to equity on exercise of warrants
    -       -       126,064       -  
Expiry of broker warrants
    -       -       556       (556 )
Stock-based compensation
    -       -       275,772       -  
                                 
Balance – March 31, 2014
    32,082,132       32,082       9,748,010       6,201,544  
 
a)  
Shares issued for services
 
During the quarter ended March 31, 2014 the Company issued 250,000 shares of common stock for services rendered to the Company.  The shares issued for services have been valued using the closing price of the Company’s common stock on the day the shares for services were issued.  A total of $315,000 in general and administrative expense has been recognized for these shares for the three months ended March 31, 2014.
 
The total share-based payment expense of $620,074 (2013 - $272,902), including stock option expense of $305,074 (2013 - $204,345), has been recognized for the three months ended March 31, 2014.  This total expense has been recognized as to $171,947 and $448,127 for research and development, and general and administrative respectively for the three months ended March 31, 2014.  The prior period expense of $272,902 has been recognized as to $152,480 and $120,422 for research and development, and general and administrative respectively for the three months ended March 31, 2013.
  
Stock Options
 
The following table sets forth the options outstanding:
 
   
Number of
stock
options
outstanding
   
Weighted
average
exercise
price
$
 
             
Balance – March 31, 2014 and December 31, 2013
    3,240,000       0.96  
                 
 
The following table summarizes stock options currently outstanding and exercisable at March 31, 2014:
 
Exercise price
$
   
Number
outstanding at
March 31,
2014
   
Weighted
average
remaining
contractual
life
(years)
   
Weighted
average
exercise
price
$
   
Number
exercisable
at
March 31,
2014
   
Exercise
price
$
 
                                 
  0.45       900,000       7.83       0.45       763,833       0.45  
  1.05       2,040,000       9.37       1.05       970,963       1.05  
  1.54       180,000       9.00       1.54       180,000       1.54  
  2.30       120,000       9.17       2.30       100,000       2.30  
          3,240,000               0.96       2,014,796       0.93  
                                             
Included in the number of stock options outstanding are 900,000 stock options granted at an exercise price of CDN $0.50.  The exercise prices shown in the above table have been converted to $0.45 USD using the period ending closing exchange rate.   Certain stock options have been granted to non-employees and will be revalued at each reporting date until they have fully vested. The stock options have been re-valued using a Black-Scholes pricing model using the following assumptions:
 
   
March 31,
2014
 
       
Dividend rate
    0 %
Volatility
 
72.8% to 75.5
%
Risk-free rate
    1.25 %
Term - years
 
0.83 to 2.38
 
 
The Company has recognized the following amounts as stock-based compensation expense for the periods noted:
 
   
Three months ended
March 31,
 
             
     
2014
$
     
2013
$
 
                 
Research and development
    171,947       152,480  
General and administrative
    133,127       51,865  
                 
      305,074       204,345  
  
During the quarter ended March 31, 2013 the Company’s functional currency changed from $CDN to $USD. As a result, certain stock options previously granted by the Company are now recognized as a long-term liability. Of the total stock option expense of $305,074 (2013 - $204,345), $275,772 (2013 - $20,846) has been recognized as additional paid in capital and $29,302 (2013 - $183,499) has been recognized as a stock option liability.
 
The aggregate intrinsic value of stock options outstanding at March 31, 2014 was $1,008,330 (2013 - $1,181,007) and the aggregate intrinsic value of stock options exercisable at March 31, 2014 was $734,111 (2013 - $764,760). As of March 31, 2014 there was $273,996 in unrecognized compensation expense that will be recognized over the next 2.4 years. No stock options granted under the Plan have been exercised to March 31, 2014.  Upon the exercise of stock options new shares will be issued.
 
A summary of status of the Company’s unvested stock options under all plans is presented below:
 
   
Number of
Options
   
Weighted
average
exercise
price
$
   
Weighted
average
grant date
fair value
$
 
                   
Unvested at December 31, 2013
    1,679,371       1.08       0.59  
Vested
    (454,167 )     1.09       0.60  
                         
Unvested at March 31, 2014
    1,225,204       1.07       0.59  
 
 Certain of the Company’s warrants have been recognized as a derivative liability (note 5). The following table summarizes all of the Company’s outstanding warrants as of March 31, 2014:
 
Description
 
Number
 
       
Balance – December 31, 2013
    24,864,009  
CDN $0.50 unit warrants (i)
    (2,189,000 )
Broker warrants(ii)
    (5,000 )
Investor warrants (iii)
    (277,313 )
         
Balance - March 31, 2014
    22,392,696  
 
i)  
Of the balance of 2,189,000 outstanding at December 31, 2013, 20,000 were exercised for no additional consideration and 2,169,000 expired on January 25, 2014.
 
ii)  
Broker warrants with an exercise price of CDN $0.50 expired on March 1, 2014.  The fair value of the warrants of $556 has been reclassified from warrants to additional paid in capital at March 31, 2014.
 
iii)  
During the three months ended March 31, 2014, 277,313 warrants were exercised for 277,313 shares of common stock.  The Company received proceeds of $221,850 from the exercise.
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet12.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Financial instruments
3 Months Ended
Mar. 31, 2014
Financial instruments [Abstract] '
Financial instruments '
6  
Financial instruments
 
The Company has financial instruments that are measured at fair value. To determine the fair value, we use the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:
 
 Level one - inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities;
   
 Level two - inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals; and
   
 Level three - unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.
 
Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy.
 
The Company’s financial instruments consist of cash and cash equivalents, other receivables, accounts payable, related party payables and derivative liability. The carrying values of cash and cash equivalents, other receivables, accounts payable and related party payables approximate their fair values due to the immediate or short-term maturity of these financial instruments.
 
As quoted prices for the derivative liability are not readily available, the Company has used a simulated probability valuation model, as described in note 2 to estimate fair value. The derivative liability utilizes Level 3 inputs as defined above.
 
The Company has the following liabilities under the fair value hierarchy:
 
        
March 31, 2014
 
          
Liability
 
Level 1
  
Level 2
  
Level 3
 
          
Derivative liability
  -   -   5,857,991 
 
         
December 31, 2013
 
           
Liability
 
Level 1
  
Level 2
  
Level 3
 
          
Derivative liability
  -   -   4,402,306 
 
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet13.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Subsequent events
3 Months Ended
Mar. 31, 2014
Subsequent Events [Abstract] '
Subsequent events '
7  
Subsequent events
 
Warrant exercises
 
Subsequent to March 31, 2014, the Company issued 8,000 shares of common stock pursuant to the exercise of warrants.  The warrants were exercised at CDN $0.50 per warrant for proceeds of CDN $4,000.
 
Share issuance
 
Subsequent to March 31, 2014, the Company issued 250,000 shares of common stock for services to an unrelated company.
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet14.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Significant accounting policies (Policies)
3 Months Ended
Mar. 31, 2014
Accounting Policies [Abstract] '
Basis of presentation '
Basis of presentation
 
The consolidated condensed interim financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles (“US GAAP”) and are presented in United States dollars. The Company’s functional currency is the United States dollar.
 
In the quarter ended March 31, 2013, the Company’s functional currency changed from Canadian dollars to United States dollars as a result of various objective factors. Therefore translation of goods and services in a foreign currency are re-measured to the functional currency of the Company with gains and losses on re-measurement recorded in the consolidated condensed interim statement of loss. Any gains and losses that were previously recorded in accumulated other comprehensive income are unchanged from the date of the change of functional currency which was January 1, 2013.
 
The accompanying consolidated condensed interim financial statements include the accounts of the Company and its wholly-owned subsidiaries, DelMar BC, Callco, and Exchangeco. All intercompany balances and transactions have been eliminated.
 
The principal accounting policies applied in the preparation of these financial statements are set out below and have been consistently applied to all periods presented.
Unaudited interim financial data '
Unaudited interim financial data
 
The accompanying unaudited March 31, 2014 consolidated condensed interim balance sheets, the consolidated condensed interim statements of loss and comprehensive loss for the three months ended March 31, 2014 and 2013, and consolidated condensed cash flows for the three months ended March 31, 2014 and 2013, and the related interim information contained within the notes to the consolidated condensed interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and the notes required by accounting principles generally accepted in the United States for complete financial statements. These consolidated condensed interim financial statements should read in conjunction with the annual financial statements of the Company as at December 31, 2013 filed in our Form 10-K filed with the Securities and Exchange Commission on March 10, 2014. In the opinion of management, the unaudited consolidated condensed interim financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair statement of the Company’s financial position at March 31, 2014 and results of its operations for the three months ended March 31, 2014 and 2013, and its cash flows for the three months ended March 31, 2014 and 2013. The results for three months ended March 31, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014 or for any other future annual or interim period.
Use of estimates '
Use of estimates
 
The preparation of consolidated condensed interim financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets and contingent liabilities as at the end or during the reporting period.  Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the derivative liability and the valuation of equity instruments issued for services.  There have been no changes to the methodology used in determining these estimates from the year ended December 31, 2013.
Loss per share '
Loss per share
 
Loss per share is calculated based on the weighted average number of common shares outstanding.  For the three month periods ended March 31, 2014 and March 31, 2013 respectively, diluted loss per share does not differ from basic loss per share since the effect of the Company’s warrants and stock options are anti-dilutive.  At March 31, 2014, potential common shares of 22,392,696 (March 31, 2013 – 24,985,009) relating to warrants and 3,240,000 (March 31, 2013 - 1,020,000) relating to stock options were excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive.
Recent accounting pronouncements '
Recent accounting pronouncements
 
The Company reviews new accounting standards as issued.  
 
The accounting pronouncements issued subsequent to the date of these financial statements that were considered significant by management were evaluated for the potential effect on these financial statements. Management does not believe any of the subsequent pronouncements will have a material effect on these financial statements as presented and does not anticipate the need for any future restatement of these financial statements because of the retro-active application of any accounting pronouncements issued subsequent to March 31, 2014 through the date these financial statements were issued.
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet15.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Derivative liability (Tables)
3 Months Ended
Mar. 31, 2014
Derivative liability [Abstract] '
Shedule of derivative liabilities '
  
March 31,
2014
$
  
December 31,
2013
$
 
       
Opening balance
  4,402,306   121,000 
         
Issuance of units
  -   3,681,372 
Dividend Warrant liability acquired on reverse acquisition
  -   2,041,680 
Warrants issued for services
  -   124,020 
Change in fair value of unexercised warrants
  1,599,349   (1,324,051)
Reclassification to equity upon exercise of warrants
  (143,664)  (241,715)
         
Closing balance
  5,857,991   4,402,306 
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet16.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Stockholders' deficiency (Tables)
3 Months Ended
Mar. 31, 2014
Stockholders' deficiency [Abstract] '
Schedule of common stock issued and outstanding '
 
   
Shares of
common stock
outstanding
   
Common
 stock
   
Additional
paid-in
capital
 
                   
Balance – December 31, 2013
    31,534,819       31,535       8,791,715  
                         
Exercise of Investor Warrants
    277,313       277       221,573  
Exercise of CDN $0.50 unit warrants
    20,000       20       17,580  
Shares issued for services (a)
    250,000       250       314,750  
Reclassification of derivative liability to equity on exercise of warrants
    -       -       126,064  
Expiry of broker warrants
    -       -       556  
Stock-based compensation
    -       -       275,772  
                         
Balance – March 31, 2014
    32,082,132       32,082       9,748,010  
 
Schedule of options outstanding under the plan '
  
Number of
stock
options
outstanding
  
Weighted
average
exercise
price
$
 
       
Balance – March 31, 2014 and December 31, 2013
  3,240,000   0.96
Schedule of stock options currently outstanding and exercisable '
Exercise price
$
  
Number
outstanding at
March 31,
2014
  
Weighted
average
remaining
contractual
life
(years)
  
Weighted
average
exercise
price
$
  
Number
exercisable
at
March 31,
2014
  
Exercise
price
$
 
                 
 0.45   900,000   7.83   0.45   763,833   0.45 
 1.05   2,040,000   9.37   1.05   970,963   1.05 
 1.54   180,000   9.00   1.54   180,000   1.54 
 2.30   120,000   9.17   2.30   100,000   2.30 
     3,240,000       0.96   2,014,796   0.93 
Schedule of stock options valuation assumptions using a Black-Scholes pricing model '
  
March 31,
2014
 
    
Dividend rate
  0%
Volatility
 
72.8% to 75.5
%
Risk-free rate
  1.25%
Term - years
 
0.83 to 2.38
 
Schedule of stock-based compensation expense '
  
Three months ended
March 31,
 
       
   
2014
$
   
2013
$
 
         
Research and development
  171,947   152,480 
General and administrative
  133,127   51,865 
         
   305,074   204,345
Schedule of unvested stock options '
  
Number of
Options
  
Weighted
average
exercise
price
$
  
Weighted
average
grant date
fair value
$
 
          
Unvested at December 31, 2013
  1,679,371   1.08   0.59 
Vested
  (454,167)  1.09   0.60 
             
Unvested at March 31, 2014
  1,225,204   1.07   0.59
Schedule of outstanding warrants '
Description
 
Number
 
    
Balance – December 31, 2013
  24,864,009 
CDN $0.50 unit warrants (i)
  (2,189,000)
Broker warrants(ii)
  (5,000)
Investor warrants (iii)
  (277,313)
     
Balance - March 31, 2014
  22,392,696 
  
i)  
Of the balance of 2,189,000 outstanding at December 31, 2013, 20,000 were exercised for no additional consideration and 2,169,000 expired on January 25, 2014.
 
ii)  
Broker warrants with an exercise price of CDN $0.50 expired on March 1, 2014.  The fair value of the warrants of $556 has been reclassified from warrants to additional paid in capital at March 31, 2014.
 
iii)  
During the three months ended March 31, 2014, 277,313 warrants were exercised for 277,313 shares of common stock.  The Company received proceeds of $221,850 from the exercise.
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet17.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Financial instruments (Tables)
3 Months Ended
Mar. 31, 2014
Financial instruments [Abstract] '
Schedule of derivative liabilities under the fair value hierarchy '
        
March 31, 2014
 
          
Liability
 
Level 1
  
Level 2
  
Level 3
 
          
Derivative liability
  -   -   5,857,991 
 
         
December 31, 2013
 
           
Liability
 
Level 1
  
Level 2
  
Level 3
 
          
Derivative liability
  -   -   4,402,306
 
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet18.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Going concern and nature of operations (Details Textual) (USD $)
3 Months Ended 12 Months Ended 48 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Dec. 31, 2013
Mar. 31, 2014
Dec. 31, 2012
Apr. 06, 2010
Nature of Operations and Going Concern [Abstract] ' ' ' ' ' '
Net loss $ (3,198,607) $ (7,405,319) '   $ (15,331,429) ' '
Accumulated deficit 19,063,113 ' 15,864,506 19,063,113 ' '
Cash and cash equivalents $ 3,474,150 $ 7,532,835 $ 4,136,803 $ 3,474,150 $ 17,782 '  
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet19.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Significant accounting policies (Details)
3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Stock Option [Member] ' '
Significant Accounting Policies [Line Items] ' '
Antidilutive securities excluded from computation of earnings per share 3,240,000 1,020,000
Warrants ' '
Significant Accounting Policies [Line Items] ' '
Antidilutive securities excluded from computation of earnings per share 22,392,696 24,985,009
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet20.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Related party transactions (Details Textual) (USD $)
3 Months Ended 12 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended
Mar. 31, 2013
Dec. 31, 2013
Mar. 31, 2014
Mar. 31, 2014
Officer [Member]
Consulting Agreement
Jan. 25, 2013
Valent Technologies, LLC
Mar. 31, 2014
Officer and Director
Accounts Payable
Dec. 31, 2013
Officer and Director
Accounts Payable
Mar. 31, 2013
Officer and Director
Consulting Agreement
Mar. 31, 2014
Director [Member]
Related Party Transaction [Line Items] ' ' ' ' ' ' ' ' '
Cash compensation to officers ' ' ' $ 32,000 ' ' ' $ 36,784 $ 24,000
Aggregate amount owing to officers and directors for fees and expenses ' 109,030 35,798 96,000 ' 35,798 74,754 110,352 '
Stock issued in exchange for reduction in royalties ' 1,150,000 ' ' 1,150,000 ' ' ' '
Payments of stock issuance costs $ 598,000 ' ' ' ' ' ' ' '
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet21.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Derivative liability - Summary of derivative liability (Details) (USD $)
3 Months Ended 12 Months Ended 48 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Dec. 31, 2013
Dec. 31, 2012
Mar. 31, 2014
Schedule Of Derivative Liabilities [Roll Forward] ' ' ' ' '
Opening balance $ 4,402,306 $ 121,000 $ 121,000 ' '
Issuance of units '   ' 3,681,372 ' '
Dividend Warrant liability acquired on reverse acquisition '   ' 2,041,680 ' '
Warrants issued for services '   ' 124,020 49,379 '
Change in fair value of derivative liability 1,599,349 2,543,574 (1,324,051) ' (43,204)
Reclassification to equity upon exercise of warrants (143,664) ' (241,715) ' '
Closing balance $ 5,857,991 ' $ 4,402,306 $ 121,000 $ 5,857,991
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet22.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Derivative liability (Details Textual)
3 Months Ended 48 Months Ended 3 Months Ended 3 Months Ended
Mar. 31, 2014
USD ($)
Mar. 31, 2014
CAD
Mar. 31, 2013
USD ($)
Mar. 31, 2014
USD ($)
Dec. 31, 2013
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Mar. 31, 2014
Investor [Member]
USD ($)
Dec. 31, 2013
Investor [Member]
Mar. 31, 2014
Dividend Warrants [Member]
Mar. 31, 2014
Warrants For Services [Member]
Derivative [Line Items] ' ' ' ' ' ' ' ' ' ' ' '
Common stock shares issued on exercise of warrants 20,000 20,000 ' ' ' ' ' ' 277,313 ' ' '
Reclassification derivative liability $ 17,600 ' ' ' ' ' ' ' $ 126,064 ' ' '
Warrant liability description of warrants expired 'The remaining 2,169,000 warrants expired on January 25, 2014. As of March 31, 2014 there are no CDN $0.50 unit warrants outstanding. 'The remaining 2,169,000 warrants expired on January 25, 2014. As of March 31, 2014 there are no CDN $0.50 unit warrants outstanding. ' ' ' ' ' ' 'The remaining 12,847,689 Investor Warrants issued with the units have been re-valued at March 31, 2014 using a simulated probability valuation model ' ' '
Closing balance of warrants outstanding 2,169,000 2,169,000 ' ' 6,000,000 6,000,000 950,000 '   ' ' ' '
Number of warrants issued 277,313 277,313 ' ' ' ' ' ' 12,847,689 ' ' '
Net proceeds from the exercise of warrants $ 221,850 4,000,000 '   $ 221,850 ' ' ' ' $ 221,850 ' ' '
Dividend rate 0.00% 0.00% ' ' ' ' ' ' 0.00% ' 0.00% 0.00%
Volatility ' ' ' ' ' ' ' ' 78.00% ' 78.00% 81.00%
Risk-free rate 1.25% 1.25% ' ' ' ' ' ' 1.44% ' 1.44% 1.62%
Term - years ' ' ' ' ' ' ' ' '4 years ' '4 years '4 years 6 months
Number Of Warrants Issued For Services ' ' ' ' ' ' ' ' ' ' ' 300,000
Exercise Price 0.5 0.5 ' ' 1.76 0.08 ' ' ' 0.8 ' 1.76
Term of warrants ' ' ' ' ' ' ' ' ' ' ' '5 years
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet23.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Stockholders' deficiency (Details) (USD $)
3 Months Ended 3 Months Ended
Mar. 31, 2013
Mar. 31, 2014
Dec. 31, 2013
Mar. 31, 2014
Common stock
Mar. 31, 2014
Additional Paid-in Capital
Mar. 31, 2014
Warrants [Member]
Schedule of common stock issued and outstanding [Line Items] ' ' ' ' ' '
Balance ' $ (3,060,299) $ (817,978) $ 31,535 $ 8,791,715 $ 6,202,100
Balance (in shares) ' ' ' 31,534,819 ' '
Exercise of Investor Warrants ' ' ' 277 221,573 '
Exercise of Investor Warrants, share ' ' ' 277,313 ' '
Exercise of CDN $0.50 unit warrants ' ' ' 20 17,580 '
Exercise of CDN $0.50 unit warrants, shares ' ' ' 20,000 ' '
Shares issued for services (a) ' ' ' 250 314,750 '
Shares issued for services (a), shares ' ' ' 250,000 ' '
Reclassification of derivative liability to equity on exercise of warrants ' ' ' '   126,064 '
Expiry of broker warrants ' ' ' '   556 (556)
Expiry of broker warrants, shares ' ' ' '   ' '
Stock-based compensation 20,846 ' ' '   275,772 '
Balance ' $ (3,060,299) $ (817,978) ' $ 9,748,010 $ 6,201,544
Balance (in shares) ' ' ' 32,082,132 ' '
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet24.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Stockholders' deficiency (Details 1) (USD $)
Mar. 31, 2014
Dec. 31, 2013
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items] ' '
Number of stock options outstanding 3,240,000 3,240,000
Weighted average exercise price (in Dollars per share) $ 0.96 $ 0.96
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet25.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Stockholders' deficiency (Details 2) (USD $)
Mar. 31, 2014
Dec. 31, 2013
Mar. 31, 2014
Stock Options
Dec. 31, 2013
Stock Options
Dec. 31, 2012
Stock Options
Dec. 31, 2011
Stock Options
Dec. 31, 2013
Stock Options
Zero Point Four Seven [Member]
Mar. 31, 2014
Stock Options
Zero Point Four Five [Member]
Mar. 31, 2014
Stock Options
One point zero five [Member]
Mar. 31, 2014
Stock Options
One Point Five Four [Member]
Mar. 31, 2014
Stock Options
Two Point Three Zero [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] ' ' ' ' ' ' ' ' ' ' '
Exercise price (in Dollars per share) ' ' ' ' ' ' ' $ 0.45 $ 1.05 $ 1.54 $ 2.3
Number of stock options outstanding 3,240,000 3,240,000 3,240,000 3,240,000 1,020,000 '   900,000 900,000 2,040,000 180,000 120,000
Weighted average remaining contractual life (years) ' ' ' ' ' ' ' '7 years 9 months 29 days '9 years 4 months 13 days '9 years '9 years 2 months 1 day
Weighted average exercise price (in Dollars per share) $ 0.96 $ 0.96 $ 0.96 $ 0.96 $ 0.47 '   $ 0.47 $ 0.45 $ 1.05 $ 1.54 $ 2.3
Number of stock options exercisable ' ' 2,014,796 ' ' ' ' 763,833 970,963 180,000 100,000
Exercise price (in Dollars per share) ' ' $ 0.93 ' ' ' ' $ 0.45 $ 1.05 $ 1.54 $ 2.3
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet26.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Stockholders' deficiency (Details 3)
3 Months Ended
Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] '
Dividend rate 0.00%
Risk-free rate 1.25%
Stock Options | Minimum [Member] '
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] '
Volatility 72.80%
Term - years '9 months 29 days
Stock Options | Maximum [Member] '
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] '
Volatility 75.50%
Term - years '2 years 4 months 17 days
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet27.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Stockholders' deficiency (Details 4) (USD $)
3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] ' '
Allocated share based compensation expense $ 305,074 $ 204,345
Research and development ' '
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] ' '
Allocated share based compensation expense 171,947 152,480
General and administrative ' '
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] ' '
Allocated share based compensation expense $ 133,127 $ 51,865
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet28.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Stockholders' deficiency (Details 5) (Stock Options, USD $)
3 Months Ended
Mar. 31, 2014
Dec. 31, 2012
Dec. 31, 2011
Stock Options ' ' '
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Number Of Shares [Roll Forward] ' ' '
Number of options unvested, beginning balance 1,679,371 444,500 '  
Number of options, vested (454,167) ' '
Number of options unvested, ending balance 1,225,204 444,500 '  
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price [Roll Forward] ' ' '
Weighted average exercise price unvested, beginning balance (in Dollars per share) $ 1.08 $ 0.47 '  
Weighted average exercise price unvested, vested (in Dollars per share) $ 1.09 ' '
Weighted average exercise price unvested, ending balance (in Dollars per share) $ 1.07 $ 0.47 '  
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Grant Date Fair Value [Roll Forward] ' ' '
Weighted average grant date fair value, unvested, beginning balance (in Dollars per share) $ 0.59 $ 0.3 '  
Weighted average grant date fair value, unvested, vested (in Dollars per share) $ 0.6 ' '
Weighted average grant date fair value, unvested, ending balance (in Dollars per share) $ 0.59 $ 0.3 '  
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet29.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Stockholders' deficiency (Details 6)
Mar. 31, 2014
Dec. 31, 2013
Stockholders Equity Note [Line Items] ' '
Closing balance of warrants outstanding 22,392,696 24,864,009
CDN $0.50 warrants ' '
Stockholders Equity Note [Line Items] ' '
Closing balance of warrants outstanding (2,189,000) '
Issued as broker warrants ' '
Stockholders Equity Note [Line Items] ' '
Closing balance of warrants outstanding (5,000) '
Investor Warrants ' '
Stockholders Equity Note [Line Items] ' '
Closing balance of warrants outstanding (277,313) '
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet30.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Stockholders' deficiency (Details Textual) (USD $)
Mar. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2010
Stockholders Equity Note [Line Items] ' ' ' '
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001 ' '
Preferred stock, shares authorized 5,000,000 5,000,000 ' '
Preferred stock, issued 1 1 '   '
Preferred stock, shares outstanding 1 1 ' '
Common stock, shares authorized 200,000,000 200,000,000 ' '
Common stock, par value (in dollars per share) $ 0.001 $ 0.001 ' '
Common stock, shares issued (in shares) 32,082,132 31,534,819 ' '
Common stock, shares outstanding (in shares) 32,082,132 31,534,819 13,050,000 8,256,250
Canadian Residents ' ' ' '
Stockholders Equity Note [Line Items] ' ' ' '
Common stock, shares outstanding (in shares) 7,169,583 ' ' '
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet31.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Stockholders' deficiency (Details Textual 1)
3 Months Ended 12 Months Ended 48 Months Ended
Mar. 31, 2014
USD ($)
Mar. 31, 2014
CAD
Mar. 31, 2013
USD ($)
Dec. 31, 2013
USD ($)
Dec. 31, 2013
CAD
Dec. 31, 2012
USD ($)
Mar. 31, 2014
USD ($)
Stockholders' deficiency [Abstract] ' ' ' ' ' ' '
common stock issued during period 250,000 250,000 ' ' ' ' '
Share-based payments $ 620,074 ' $ 272,902 $ 2,146,766 ' $ 1,130,240 $ 4,024,311
General and administrative expense 966,923 ' 920,377 1,578,041 ' ' 6,383,235
stock option expense 305,074 ' 204,345 ' ' ' '
Research and development expense $ 618,869 ' $ 631,947 $ 568,725 ' ' $ 5,604,809
Number of options, granted 900,000 900,000 ' 900,000 900,000 ' '
Exercise price $ 0.45 0.5 ' $ 0.47 0.5 ' '
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet32.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Stockholders' deficiency (Details Textual 2)
3 Months Ended 12 Months Ended 48 Months Ended
Mar. 31, 2014
USD ($)
Mar. 31, 2014
CAD
Mar. 31, 2013
USD ($)
Dec. 31, 2013
USD ($)
Mar. 31, 2014
USD ($)
Jan. 25, 2014
Stockholders' deficiency [Abstract] ' ' ' ' ' '
stock option expense $ 305,074 ' $ 204,345 ' ' '
Stock option recognized as additional paid in capital ' ' 20,846 ' ' '
Stock option liability 241,863 ' 183,499 212,561 241,863 '
Aggregate intrinsic value of stock options outstanding 1,008,330 ' 1,181,007 ' 1,008,330 '
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value 734,111 ' 764,760 ' 734,111 '
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition '2 years 4 months 24 days '2 years 4 months 24 days ' ' ' '
Unrecognized compensation expense 273,996 ' ' ' 273,996 '
Exercise of CDN $0.50 unit warrants 556 556 ' 0.8 ' '
Number Of Warrants Expired ' ' ' ' ' 2,169,000
Exercise period of warrants expired 'January 25, 2014 'January 25, 2014 ' ' ' '
Number of warrants exercisable 277,313 277,313 ' 20,000 277,313 '
Closing balance of warrants outstanding 22,392,696 22,392,696 ' 24,864,009 22,392,696 '
Proceeds from Warrant Exercises $ 221,850 4,000,000 '   ' $ 221,850 '
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet33.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Financial instruments (Details) (USD $)
Mar. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] ' ' '
Derivative liability $ 5,857,991 $ 4,402,306 $ 121,000
Level 1 ' ' '
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] ' ' '
Derivative liability '   '   '
Level 2 ' ' '
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] ' ' '
Derivative liability '   '   '
Level 3 ' ' '
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] ' ' '
Derivative liability $ 4,402,306 $ 4,402,306 '
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/Sheet34.html Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
Subsequent events (Details Textual)
3 Months Ended 48 Months Ended
Mar. 31, 2014
USD ($)
Mar. 31, 2014
CAD
Mar. 31, 2013
USD ($)
Mar. 31, 2014
USD ($)
Dec. 31, 2013
Dec. 31, 2013
Dec. 31, 2013
Issued as broker warrants
Subsequent Event [Line Items] ' ' ' ' ' ' '
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 8,000 8,000 ' ' 5,250,000 5,250,000 '
Proceeds from Warrant Exercises $ 221,850 4,000,000 '   $ 221,850 ' ' '
Class of Warrant or Right, Exercise Price of Warrants or Rights 0.5 0.5 ' ' 1.76 0.08 1.2
------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477 Content-Location: file:///C:/b3455d59_8392_45b7_954f_c88f7fbc1477/Worksheets/filelist.xml Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii" ------=_NextPart_b3455d59_8392_45b7_954f_c88f7fbc1477--